Welcome to our dedicated page for Alx Oncology Holdings news (Ticker: ALXO), a resource for investors and traders seeking the latest updates and insights on Alx Oncology Holdings stock.
ALX Oncology Holdings Inc. reports company news around a clinical-stage oncology pipeline led by evorpacept, an investigational CD47 inhibitor designed to address a cancer immune-evasion signal. Updates commonly cover clinical data presentations, biomarker analyses involving CD47 expression, and studies of evorpacept combinations in HER2-positive cancers, including breast and gastric cancer settings.
The company also reports development activity for ALX2004, an EGFR-targeted antibody-drug conjugate for EGFR-expressing solid tumors. Other recurring updates include quarterly financial results, research and development spending, cash runway commentary, registered offerings of common stock and pre-funded warrants, leadership appointments, investor conference participation, and Nasdaq inducement equity grants.
ALX Oncology (Nasdaq: ALXO) announced an upcoming oral presentation of their Phase 1b study results for ALX148 at the ESMO World Congress on Gastrointestinal Cancer, scheduled for July 3, 2021. The study evaluates ALX148 in combination with trastuzumab, ramucirumab, and paclitaxel for patients with advanced gastric or gastroesophageal junction cancer. This presentation may highlight the therapeutic potential of ALX148 and its impact on treatment outcomes for patients, while contributing to the ongoing clinical development of their immuno-oncology pipeline.
ALX Oncology announced the end of the post-grant review period for U.S. Patent 10,696,730 concerning the composition of matter for ALX148, effective March 30, 2021. This patent secures coverage for ALX148 until at least 2036, bolstering its intellectual property. ALX148 is designed to enhance anti-cancer therapy effectiveness, demonstrating promise in both solid tumors and hematologic malignancies. The patent reinforces confidence as the company prepares for Phase 2 studies in various cancer types, including myelodysplastic syndromes and head and neck cancers.
ALX Oncology Holdings Inc. (ALXO) reported its financial results for Q4 and FY 2020, highlighting progress with its lead candidate ALX148 in immuno-oncology. Positive Phase 1b data showed promise in treating solid tumors, including gastric and head and neck cancers. The company plans to report full Phase 1b results and initiate multiple clinical trials in 2021, including two Phase 2 studies in HNSCC and a collaboration with Zymeworks. Despite these advancements, the company reported a net loss of $50.9 million for FY 2020, a significant increase from $23.3 million in 2019.
ALX Oncology (Nasdaq: ALXO) announced the appointment of Sophia Randolph, M.D., Ph.D., to its Board of Directors. As the current Chief Medical Officer, Dr. Randolph has over 15 years of biopharmaceutical experience, including leadership roles at Pfizer and Merck. Her expertise will enhance the board's capabilities as the company prepares for multiple clinical trials this year. This strategic addition aims to strengthen corporate strategy and drive clinical development of ALX148, a promising treatment targeting the CD47 checkpoint pathway.
ALX Oncology (Nasdaq: ALXO) has partnered with Tallac Therapeutics to co-develop a novel cancer immunotherapeutic, SIRPα TRAAC. This collaboration aims to create a first-in-class anti-SIRPα antibody conjugated to a TLR9 agonist, enhancing the company’s immuno-oncology pipeline targeting the CD47 checkpoint pathway. Both firms will equally share development costs and potential profits. The initiative is set to potentially revolutionize cancer treatment by leveraging innate and adaptive immune responses. A conference call is scheduled for March 5, 2021, to discuss further details.
BURLINGAME, Calif., March 02, 2021 – ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced participation in a fireside chat at H.C. Wainwright’s Global Life Sciences Conference on March 9-10, 2021. Jaume Pons, Ph.D., and senior executives will provide insights during the virtual event. A prerecorded chat is set to release on March 9, 2021, at 7:00 a.m. Eastern Time, accessible via ALX Oncology's website. ALX Oncology focuses on immuno-oncology, developing therapies to block the CD47 checkpoint pathway, with its lead candidate ALX148 showing promising clinical results.
ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced key milestones for 2021 following a successful 2020, which included an IPO and a secondary offering that raised approximately $394 million. The company initiated clinical trials for its lead candidate, ALX148, showing promising data in treating various cancers. Upcoming milestones include the initiation of multiple Phase 1 and 2 trials, with significant data readouts expected. ALX Oncology's cash reserves are projected to sustain operations through 2024, supporting ongoing clinical development and collaborations.
ALX Oncology (Nasdaq: ALXO) announced that Jaume Pons, Ph.D., its CEO, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on January 12 at 10:50 am ET. The presentation will be accessible via a live webcast, available on the Investors section of ALX Oncology’s website. Following the event, a replay of the webcast will be archived for 30 days. ALX Oncology focuses on developing therapies that block the CD47 checkpoint pathway, with its lead candidate, ALX148, showing promise in treating various cancers.
ALX Oncology Holdings Inc. (NASDAQ: ALXO) has been selected for addition to the NASDAQ Biotechnology Index, effective prior to market open on December 21, 2020. The NASDAQ Biotechnology Index tracks biotechnology and pharmaceutical companies on NASDAQ, calculated under a modified capitalization-weighted methodology. ALX Oncology focuses on therapies that block the CD47 checkpoint pathway, with its lead candidate, ALX148, showing promising clinical responses for various malignancies.
ALX Oncology Holdings Inc. (Nasdaq: ALXO) has successfully closed its underwritten public offering of 2,737,000 shares of common stock at a price of $76.00 per share, raising approximately $208.0 million in gross proceeds. This includes the full exercise of the underwriters' option for an additional 357,000 shares. The offering was managed by Jefferies, Credit Suisse, and Piper Sandler, among others. The funds raised will likely support the ongoing clinical development of ALX148, a promising treatment targeting CD47 in various cancers.